HC Wainwright Expects Higher Earnings for Kodiak Sciences

Key Points

• HC Wainwright raised its Q3 2025 earnings estimate for Kodiak Sciences to ($1.05) per share, up from a previous estimate of ($1.09), maintaining a "Neutral" rating and a target price of $5.00.
• JPMorgan upgraded Kodiak Sciences from "underweight" to "neutral" with a price objective of $15.00, while Barclays increased its target from $4.00 to $7.00.
• Kodiak Sciences has a market capitalization of $500.75 million, with a one-year stock price range from $1.92 to $11.60, and approximately 89.06% of the stock is owned by institutional investors.

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Equities research analysts at HC Wainwright raised their Q3 2025 earnings estimates for shares of Kodiak Sciences in a report issued on Monday, August 18th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($1.05) for the quarter, up from their prior estimate of ($1.09). HC Wainwright currently has a "Neutral" rating and a $5.00 target price on the stock. The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences' Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($4.21) EPS, FY2026 earnings at ($4.45) EPS, FY2027 earnings at ($4.40) EPS, FY2028 earnings at ($3.42) EPS and FY2029 earnings at ($1.87) EPS.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.02).

Other research analysts have also issued research reports about the stock. JPMorgan Chase & Co. raised shares of Kodiak Sciences from an "underweight" rating to a "neutral" rating and set a $15.00 target price on the stock in a research note on Thursday, August 14th. Barclays raised their target price on shares of Kodiak Sciences from $4.00 to $7.00 and gave the company an "underweight" rating in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $11.75.

Kodiak Sciences Stock Performance

KOD traded up $0.49 during midday trading on Wednesday, hitting $10.20. The company had a trading volume of 669,916 shares, compared to its average volume of 704,460. The company has a market capitalization of $538.76 million, a PE ratio of -2.68 and a beta of 2.41. Kodiak Sciences has a twelve month low of $1.92 and a twelve month high of $11.60. The firm's 50-day simple moving average is $6.18 and its 200-day simple moving average is $4.56.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. US Bancorp DE boosted its stake in Kodiak Sciences by 131.7% during the 1st quarter. US Bancorp DE now owns 9,282 shares of the company's stock worth $26,000 after acquiring an additional 5,276 shares during the last quarter. Vontobel Holding Ltd. bought a new position in Kodiak Sciences during the 1st quarter worth approximately $28,000. Headlands Technologies LLC boosted its stake in Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company's stock worth $30,000 after acquiring an additional 5,815 shares during the last quarter. Walleye Capital LLC bought a new position in Kodiak Sciences during the 1st quarter worth approximately $49,000. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in Kodiak Sciences by 21.7% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company's stock worth $56,000 after acquiring an additional 2,691 shares during the last quarter. Institutional investors own 89.06% of the company's stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.